MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Catalyst Pharmaceuticals Total Assets 2011-2026 | CPRX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Catalyst Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 851 M | 470 M | 376 M | 238 M | 192 M | 112 M | 60.4 M | 85.4 M | 41.7 M | 60.1 M | 43.9 M | 25.4 M | 16.8 M | 6.25 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 851 M | 6.25 M | 184 M |
Quarterly Total Assets Catalyst Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.05 B | 972 M | 909 M | 851 M | 772 M | 706 M | 647 M | 470 M | 413 M | 444 M | 407 M | 376 M | 333 M | 267 M | 247 M | 238 M | 223 M | 209 M | 197 M | 192 M | 192 M | 192 M | 192 M | 112 M | 112 M | 112 M | 112 M | 60.4 M | 60.4 M | 60.4 M | 60.4 M | 85.4 M | 85.4 M | 85.4 M | 85.4 M | 41.7 M | 41.7 M | 41.7 M | 41.7 M | 60.1 M | 60.1 M | 60.1 M | 60.1 M | 43.9 M | 43.9 M | 43.9 M | 43.9 M | 25.4 M | 25.4 M | 25.4 M | 25.4 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 6.25 M | 6.25 M | 6.25 M | 6.25 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.05 B | 6.25 M | 209 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
539 M | $ 18.38 | -0.68 % | $ 2.7 B | USA |
 |
Amgen
AMGN
|
91.8 B | $ 344.65 | 0.81 % | $ 185 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
1.39 B | $ 71.99 | 3.84 % | $ 9.63 B | USA |
 |
Biogen
BIIB
|
28 B | $ 178.18 | -0.95 % | $ 25.9 B | USA |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.65 | 1.92 % | $ 16.6 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
89.3 M | $ 2.96 | 7.64 % | $ 167 M | China |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Burford Capital Limited
BUR
|
3.11 B | $ 9.83 | 1.44 % | $ 1.59 B |  Britain |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.12 M | $ 4.16 | 3.74 % | $ 9.05 B |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.18 | 0.32 % | $ 7.65 B |  Australia |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Compugen Ltd.
CGEN
|
115 M | $ 1.86 | 1.1 % | $ 167 M | Israel |
 |
Aptose Biosciences
APTO
|
10.1 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Celldex Therapeutics
CLDX
|
792 M | $ 24.86 | 1.06 % | $ 1.6 M | USA |
 |
Cellectis S.A.
CLLS
|
384 M | $ 3.87 | 2.22 % | $ 116 M | France |
 |
Aeglea BioTherapeutics
AGLE
|
608 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
242 M | $ 1.41 | - | $ 264 M | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
1.18 B | $ 224.87 | -0.54 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
841 M | $ 40.98 | 2.78 % | $ 4.23 B | USA |
 |
BioNTech SE
BNTX
|
22.5 B | $ 110.01 | -3.29 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
58.8 M | - | - | $ 269 M | USA |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | Canada |
 |
Autolus Therapeutics plc
AUTL
|
783 M | $ 1.39 | 1.5 % | $ 355 M | Britain |
 |
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | USA |
 |
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | USA |
 |
Cardiff Oncology
CRDF
|
97.2 M | $ 1.73 | -1.43 % | $ 82.4 M | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
283 M | - | -15.15 % | $ 60.3 M | Britain |
 |
DBV Technologies S.A.
DBVT
|
65.7 M | $ 21.75 | 0.65 % | $ 2.11 B | France |
 |
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
3.5 B | $ 14.25 | 4.13 % | $ 4.4 B | USA |
 |
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Atreca
BCEL
|
155 M | - | -11.76 % | $ 5.79 M | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
490 M | $ 6.72 | 2.05 % | $ 1.39 B | USA |